IBEX Technologies
CVE:IBTIBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.
(TAM)
NYSE:TAMTaminco Corp is a producer of alkylamines and alkylamine derivatives. The Company's products are used by its customers in the manufacturing of everyday products primarily for the agriculture, water treatment, personal and home care, animal nutrition and oil and gas end-markets. It operates in 19 countries with seven production facilities and, as of December 31, 2012, had an installed production capacity of 1,272 thousand tons. The Company has three business segments: Functional Amines, Specialty Amines, and Crop Protection. In March 2014, the Company announced that it completed the acquisition of the formic acid business of Kemira Oyj. Its main shareholder is Eastman Chemical Company.
